Introduction: Background on Morphea/Scleroderma {#Sec1}
===============================================

Scleroderma is a chronic autoimmune disease associated with cutaneous, joint, and internal organ involvement. Cutaneous scleroderma is characterized by enhanced fibroblast activity leading to hypertrophic dermal collagen. There are localized and systemic forms of scleroderma. The localized forms include morphea and linear scleroderma. Localized scleroderma has a better prognosis and does not involve internal organs. There are currently no curative treatments for scleroderma. Current treatments include immunosuppressants; intralesional, topical, and oral steroids; topical vitamin D; and phototherapy. This review serves to provide insight into the use of phototherapy in the management of scleroderma. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Phototherapy in Dermatology {#Sec2}
===========================

Phototherapy modalities utilize specific wavelengths of the electromagnetic spectrum to disrupt the dysfunctional and pathologic tissue that has developed in some patients with skin disease. Various phototherapy modalities possess anti-inflammatory effects \[[@CR1]\]. The longer the wavelength of phototherapy, the deeper in the dermis it penetrates \[[@CR2]\]. Current phototherapeutic modalities being used for dermatoses include broadband ultraviolet B (UVB 290--320 nm), narrowband UVB (311--313 nm), excimer laser (308 nm), ultraviolet A (UVA 320--400 nm), ultraviolet A1 (UVA1 340--400 nm), psoralen and UVA (PUVA), and extracorporeal photochemotherapy.

Mechanism Behind Phototherapeutic Modalities Used in Scleroderma {#Sec3}
================================================================

A common theory behind the mechanism of phototherapy in scleroderma is that light is converted to chemical energy resulting in the increase of reactive oxygen species or singlet oxygen production, which can modulate the expression of cytokines \[[@CR3], [@CR4]\]. Ultraviolet radiation includes UVA and UVB therapy, with UVA1 studied the most. UVA1 can have an output categorized as low (10--30 J/cm^2^), moderate (40--70 J/cm^2^), or high (up to 130 J/cm^2^).

UVA1 radiation increases collagenase \[also known as the matrix metalloproteinase-1 (MMP-1)\] gene, mRNA, and protein expression by fibroblasts \[[@CR5]--[@CR9]\]. In mice models, UVA1 radiation reduces fibroblast proliferation in a dose-dependent fashion \[[@CR10], [@CR11]\]. Additionally, UVA1 radiation administered three times a week showed decreased hydroxyproline and collagen levels in a dose-dependent fashion \[[@CR11]\]. The quality of the collagen is altered after UVA1 therapy, as collagen appears less dense and smoother compared to before treatment \[[@CR12]\]. Decorin (a proteoglycan component of connective tissue) mRNA levels are lower in lesional scleroderma versus non-lesional skin, and decorin levels are increased after UVA1 phototherapy \[[@CR13]\]. Transforming growth factor beta (TGF-β) protein levels (TGF-β is profibrotic) are inversely correlated with decorin levels. On the other hand, another study showed that after UVA1 phototherapy, decorin was decreased in the upper to middle dermis, although decorin slightly increased in the papillary dermis \[[@CR14]\]. In patients, UVA has been shown to reduce collagen I, collagen III, and TGF-β and increase interferon-γ \[[@CR9]\]. UVB radiation increases alpha melanocyte-stimulating hormone (α-MSH) receptor synthesis in keratinocytes and melanocytes \[[@CR15]\]. Human fibroblast dermal cultures treated with α-MSH demonstrated an increase in MMP-1 mRNA, indicating that α-MSH may be one of UVB\'s mediators of anti-fibrosis \[[@CR16]\].

The source of the mediators that contribute to the reduction in sclerosis comes mostly from the dermis. Subsequently, certain parts of the dermis may be impacted more than others. An image analyzer showed a greater reduction in collagen fibers in the upper and middle dermis and less reduction in the lower dermis \[[@CR12]\]. In 18 patients treated with UVA1, the MMP-1 level was higher in the papillary layers and lower in the reticular layers \[[@CR17]\]. The anti-fibrotic effects of phototherapy may not come exclusively from the dermis. Samples taken 18 h after the final UVA1 treatment in a set of patients showed an increase in interstitial collagenase in the upper layer of keratinocytes, melanocytes, and endothelial cells \[[@CR5]\].

Evidence supports the regimen of multiple UVA1 therapy sessions a week. The anti-sclerotic effects of a single exposure of UVA1 effects are typically seen to last less than 1 week. In human skin, mRNAs of type I and III procollagen were decreased and MMP-3 was increased after 3 days of a single UVA1 dose \[[@CR18]\]. MMP-1 and MMP-3 were upregulated for 3 to 5 days, while procollagen levels were suppressed for at least 7 days \[[@CR18]\]. In this small study, anti-fibrotic responses became refractory to multiple UVA1 exposures over the course of 1 week, as repeated exposures weekly showed no reduction in type I procollagen levels \[[@CR18]\].

UVA1 therapy can have an immunomodulatory effect on lesional skin. UVA1 can reduce inflammation in the dermis \[[@CR12]\]. UVA1 causes apoptosis of T-cells \[[@CR19]\]. Patients with morphea exposed to UVA1 with a dose of 30 J/cm^2^ and a cumulative dose of 900 J/cm^2^ were found to have an increase in CD34^+^ dendritic cells \[[@CR20]\]. Human beta defensin\[s\] (HBD), interleukin (IL)-6 and IL-8 are downregulated in patients with localized scleroderma treated with UVA1 phototherapy \[[@CR6]\]. On the other hand, another study showed that UVA1 induces MMP-1 through a mechanism involving IL-1 and IL-6 \[[@CR21]\].

UVA1 radiation may induce oxidative stress, as evidenced by an increase in UVA1-induced heme oxygenase-1 in fibroblasts \[[@CR7]\]. Glutathione was lower in systemic sclerosis (SSc) fibroblasts than control samples, but glutathione was increased and became equivalent between normal and SSc fibroblasts after in vitro irradiation with UVA1 \[[@CR8]\]. Thus, the SSc fibroblasts may be more susceptible to phototherapy-induced oxidative stress than normal fibroblasts \[[@CR8]\]. Additionally, heme oxygenase-1 may reduce fibrotic conditions via TGF-β \[[@CR22]\]. UVA1 may play a role in angiogenesis. In patients exposed to UVA1 phototherapy for 14 weeks, there was an increase in CD34^+^ cells and an increase in vascular endothelial growth factor (VEGF) \[[@CR23]\]. The neuroendocrine system may be involved, as UVA1 therapy decreases dermal expression of neuron-specific enolase, which correlated with softening of skin lesions in patients with SSc with acral lesions \[[@CR24]\].

UVB phototherapy results in DNA damage, forming cyclobutane pyrimidine dimers between nucleotides \[[@CR25]\]. There is evidence that broadband UVB can induce interstitial collagenase, stromelysin, and IL-6 \[[@CR26]\]. There may be an interplay between these enzymes and cytokines \[[@CR26]\]. Broadband UVB radiation can induce production of MMP-1 in fibroblasts \[[@CR27]\]. When keratinocytes are exposed to UVB, there is an increase in IL-1α and IL-6, which induced MMP-1 \[[@CR27]\]. Human keratinocytes cultured in a model system exposed to 300 J/cm^2^ of broadband UVB produced IL-1α, IL-6, and tumor necrosis factor alpha (TNF-α) \[[@CR28]\].

PUVA is another modality that can be used for scleroderma. PUVA can lead to apoptosis of T-cells in the dermis \[[@CR19]\]. In patients with SSc treated with PUVA, the majority of patients experienced an increase in circulating TNF-α levels, E-selectin, and vascular cell adhesion molecule (VCAM). In the majority of patients, there was a reduction in VEGF and TGF-β \[[@CR29]\]. On the other hand, in patients with morphea treated with PUVA, there was a fall in serum VCAM molecules and an increase in TNF-α in most patients \[[@CR30]\]. In a bleomycin-induced scleroderma rat model, PUVA treatment reduced dermal thickness and hydroxyproline content and downregulated expression of type I and III collagen genes \[[@CR10]\]. In one patient with SSc, treatment with oral PUVA therapy three times a week for 4 weeks resulted in loosening of collagen, reduction in edema, and decreased CD34^+^ cells \[[@CR31]\]. Bath PUVA treatment has effects on collagen cross-links in human skin samples of scleroderma, reducing hydroxylysylpyridinoline and lysylpyridinoline \[[@CR32]\]. UVA1 treatment affected collagen fibrils mostly in the upper reticular dermis \[[@CR33]\], whereas PUVA affected collagen fibrils in the upper and middle reticular layers \[[@CR33]\]. Additionally, collagen fibrils decreased and new fibrils developed, suggesting UVA1 and PUVA phototherapies' impact on sclerotic lesions occurs via collagen degradation and new collagen synthesis \[[@CR33]\].

Other modalities have also been studied. Photodynamic therapy (PDT) with 5-aminolevulinic acid (5-ALA) treatment of scleroderma fibroblasts increased MMP-1 and MMP-3, and there was a decrease in collagen type 1 mRNA as early as 6 h after treatment \[[@CR34]\]. Keratinocytes exposed to PDT with 5-ALA had an increase in IL-1α and TNF-α \[[@CR35]\]. In fibroblasts that were incubated with keratinocytes pre-exposed to PDT with 5-ALA, there was an increase in MMP-1 and MMP-3; Karrer et al. \[[@CR35]\] subsequently suggested paracrine signaling between the phototherapy exposed keratinocytes and the fibroblasts. Furthermore, an IL-1 antagonist reversed the induction of MMP-1 and MMP-3 in fibroblasts \[[@CR35]\]. Blue light up to 453 nm is toxic to cultured T cells, causing apoptosis, but was nontoxic for other skin cell types \[[@CR36]\].

The Use of Phototherapy in Dermatology {#Sec4}
======================================

Phototherapy is commonly used for many dermatoses, but there is less usage for scleroderma. Of 653 patients using phototherapy in a Brazilian clinic, 11 were there for scleroderma treatment \[[@CR37]\]. In a multi-center response from 155 British pediatric physicians, PUVA was the most popular phototherapy modality (38%), followed by narrowband UVB (23%) and UVA1 (16%) for morphea \[[@CR38]\]. These same clinicians were also asked what would be the best treatment option overall in their opinion for active morphea: 17% responded phototherapy and about 2/3 of these responses were for UVA1, which was only accessible to 27% of respondents \[[@CR38]\]. Phototherapy for adult skin disorders is almost exclusively provided by dermatologists \[[@CR39]\]. In a survey of physicians treating juvenile localized scleroderma in the UK, 19 of 28 pediatric dermatologists used UV therapy, whereas 0 of 10 pediatric rheumatologists used UV therapy \[[@CR40]\]. A self-reported survey of dermatologists and rheumatologists revealed that 20% of dermatologists (*n* = 40) and 10.6% of pediatric dermatologist (*n* = 47) used phototherapy \[[@CR41]\].

Clinical Evidence of Phototherapy's Efficacy {#Sec5}
============================================

Search Method {#Sec6}
-------------

A PubMed search was performed with the Boolean search terms 'scleroderma' OR 'morphea' OR 'crest' AND 'phototherapy.' The search years yielded were from 1978 to 2016. Clinical articles in a non-English language were excluded.

UVA1 {#Sec8}
----

UV therapy for patients with localized scleroderma was introduced as PUVA in 1994 \[[@CR42]\]. In 1995, Kerscher et al. \[[@CR43]\] reported that low-dose UVA1 phototherapy could be used in linear scleroderma. It is unclear whether there is an association between initial skin disease duration and response to UVA1 therapy. A study of ten patients with sclerodermic lesions determined that there was no correlation between disease duration and clinical response with UVA1 \[[@CR44]\].

Table [1](#Tab1){ref-type="table"} lists the clinical reports of UVA1′s efficacy in scleroderma or morphea. It is important to note that covered sclerotic lesions show less improvement after UVA1 therapy \[[@CR45]\]. Ultrasound is an objective measure used to assess skin thickness in several UVA studies. Fourteen patients with localized scleroderma treated with UVA1 were evaluated with a 13-MHz ultrasound, and dermal thickness was increased before therapy and decreased from 3.11 ± 1.54 to 2.26 ± 0.86 \[[@CR46]\]. Other studies have also supported a correlation of a decrease in dermal thickness when treating with UVA1 therapy \[[@CR47]\].Table 1Studies of UVA1, UVB, and PUVA treatment in patients with scleroderma or morpheaStudy (clinical trial, case report, etc.)Patients^a^DiseaseTreatment modalityTreatment durationCumulative dose (J/cm^2^)Duration of phototherapyTotal treatmentsImprovement outcome (clinical, radiologic)Was the patient(s) reported to be on another treatment concurrently?AuthorRandomized, controlled, single-blinded controlled study9Systemic sclerosis (acrosclerosis)UVA140 J/cm^2^ 3 times a week168014 weeks42Modified Rodnan skin scoring: no improvement seen in control vs. placeboNoDurand et al. \[[@CR69]\]Randomized, controlled trial64Localized sclerodermaUVA1/UVBTwenty-seven patients received 20 J/cm^2^ UVA1; 18 patients received 50 J/cm^2^ UVA1; 19 patients received narrowband UVB. All phototherapy was performed 5 times a weekLow dose 800, medium dose 20008 weeks40Reduction in clinical scores in all groups. No statistical difference between the UVA groups. There was a statistically significant difference between UVB and medium dose UVA1NoKreuter et al. \[[@CR70]\]Controlled study8Localized sclerodermaUVA148 J/cm^2^ 4 times a week9605 weeks20At 12 weeks no significant difference between skin elasticity in treated versus control skin. Fast Fourier transform did not show a significant change after 12 weeks. Skin softening was clinically noted after 7 weeksNode Rie et al. \[[@CR71]\]Prospective uncontrolled study18Systemic sclerosis (acrosclerosis)UVA130 J/cm^2^ 4 times a week for 8 weeks, then 3 times a week for 6 weeks150014 weeks50Improvement in clinical score and dermal thickness in 16 patients with softening of the skin and increased finger mobility. Follow-up in 6 months showed stable clinical outcome in most patientsEight patients were on other systemic medicationsKreuter et al. \[[@CR17]\]Prospective uncontrolled study14Localized sclerodermaUVA120 and 70 J/cm^2^ were given 4 times a week for 5 weeks, then 2 times a week for 5 weeksLow dose 600, medium dose 210010 weeks30Skin thickness decreased in patients in both groups, but more so in the higher dosage group at a 12-month follow-upNoSator et al. \[[@CR45]\]Prospective uncontrolled study35Localized sclerodermaUVA130 J/cm^2^ 3--5 times a week900--1350 (mean 1180.29)10--15 weeks30--45 (mean 41.14)The mean follow-up period was 21.63 months. In five patients, a partial relapse was observed. Two of the five patients reported reappearance of new lesions after 12 months. Softening of plaques and improvement in 29 of 35 patients (82.85%). Dermal thickness decreased after therapy in 14 of 35 patientsNoSu et al. \[[@CR46]\]Prospective uncontrolled study20Localized sclerodermaUVA120 J/cm^2^ 4 times a week for 6 weeks and once a week for another 6 weeks60012 weeks30More than 80% of the lesions disappeared in 18 patients. Decreased dermal thicknessNoKerscher et al. \[[@CR47]\]Prospective uncontrolled study10Localized sclerodermaUVA120 J/cm^2^ 4 times a week4806 weeks24Lesions started to regress after 15 treatments. More than 80% of lesions regressed after 24 treatmentsNoKerscher et al. \[[@CR43]\]Prospective uncontrolled study34Localized sclerodermaUVA16 patients were treated with medium dose and 28 were treated with high dose. Both groups treated 3 times a week5234 ± 3611UnavailableUnavailablePatients reported an improvement of at least 25%UnknownJacobe et al. \[[@CR48]\]Prospective uncontrolled study17Localized sclerodermaUVA1Ten patients with high dose 130 J/cm^2^. Seven patients with low-dose 20 J/cm^2^. Patients treated 4 times a week during 5 weeks, then twice a week for 5 weeksLow dose 600, high dose 390010 weeks30Softening of skin lesions in all high dose patients, and complete clearance in four of ten patients. Three months after treatment, nine of ten patients have clinical stability. Two of seven patients in the low-dose group reported improvement or had clinical signs of improvement. Skin thickness by ultrasound was reduced in all patientsNoStege et al. \[[@CR72]\]Prospective uncontrolled study13Localized sclerodermaUVA1Unavailable750--12503--5 weeks20.8 ± 4.0Modified Rodnan score improvement. Reduction of skin thickness in 11 patients. Skin elasticity increased in ten patientsNoAndres et al. \[[@CR73]\]Prospective uncontrolled study7MorpheaUVA130 J/cm^2^ 3 times a week90010 weeks30Clinical improvement in induration of all patients. One patient reported improved elbow joint mobility. After a 6--9-month follow-up, there was clinical stabilityNoCamacho et al. \[[@CR20]\]Prospective uncontrolled study3MorpheaUVA120 J/cm^2^ 4 times a week for 6 weeks, then once a week for 6 weeks60012 weeks30Resolution of sclerotic plaques in all patients. No signs of recurrence after 2 year follow-upNoGruss et al. \[[@CR74]\]Prospective uncontrolled study19Childhood morpheaUVA120 J/cm^2^ 4 times a week80010 weeks40Mean clinical score (skin inspection and palpation every week) improved--relative reduction of 67.1%. The treatment outcome remained stable for at least 1 year in all patientsTopical calcipotriol 0.005% twice a dayKreuter et al. \[[@CR64]\]Prospective uncontrolled study47MorpheaUVA1Six were treated with medium dose (50--60 J) and 41 were treated with high dose (120 J) UVA1; 3 times a week5329 ± 4398UnavailableUnavailablePatients reported an improvement of at least 25%May/may notJacobe et al. \[[@CR48]\]Prospective uncontrolled study30MorpheaUVA13 times a week, 21 cases of morphea were treated with UVA 20 J/cm^2^ for 20 sessions. Nine cases of morphea received 10 J/cm^2^High dose 400, low dose 2006 + weeks20No difference in improvement between the 10 and 20 J/cm^2^ group. Overall, 18 patients reported softening of the skin lesions. Twelve patients reported moderate improvement, four patients reported good improvement, and two patients reported very good improvementNoEl-Mofty et al. \[[@CR9]\]Prospective uncontrolled study49/MMorpheaUVA170 J/cm^2^ 5 times a week14004 weeksUnavailableDurometer scores improved significantly during first 3 weeks, and borderline significantly the last week. Improvements were maintained at 4-month follow-upNoKroft et al. \[[@CR44]\]Prospective uncontrolled study4Systemic sclerosisUVA160 J/cm^2^ 5 times a week510--1740Unavailable9--29Skin elasticity before treatment was improved as assessed by cutometer. The mean thermography and joint passive range of motion both increased after treatmentUnknownMorita et al. \[[@CR75]\]Prospective uncontrolled study83Morphea (63), systemic sclerosis (15)UVA5, 10, and 20 J/cm^2^100, 200, 4006 + weeks20Clinical improvement. No difference between the groupsNoEl-Mofty et al. \[[@CR51]\]Prospective uncontrolled study12MorpheaUVA20 J/cm^2^ 3 times a week4006 + weeks2090% cure of early lesions, 50% cure of "late" lesionsNoEl-Mofty et al. \[[@CR12]\]Prospective uncontrolled study11SclerodermaOral + topical PUVA, Narrowband UVBUnavailableUnavailableUnavailableMean 10Most lesions had a decreased dermal thickness on ultrasound at 12 weeksUnknownBuense et al. \[[@CR56]\]Prospective uncontrolled study12Systemic sclerosisPUVA, bath or oralUnavailableMedian cumulative exposure 68.25UnavailableMedian 24Improvement in 11 patientsNoUsmani et al. \[[@CR29]\]Prospective uncontrolled study4Localized sclerodermaPUVA cream4 times a week. Maximum single dose of 3.5 J/cm^2^89.5 (range 67.5--121)Unavailable30Decrease in dermal thickeningNoGrundmann-Kollmann et al. \[[@CR76]\]Prospective uncontrolled study4Systemic sclerosisPUVA oral3 times a week for 10 weeksMean of 70.5 (range 50.5--92.0)10 weeks30Improvement of skin, joint mobility, grip strength, and skin thickness in three of four patientsNoHofer and Soyer \[[@CR77]\]Prospective uncontrolled study17Localized sclerodermaPUVA bath0.2--0.5 J/cm^2^ up to 1.2--3.5 J/cm^2^ per treatment. First 20 treatments 4 times a week, twice a week for the following ten treatments, and once a week for the last four treatmentsMean UVA dose of 41.5 (range 15.7--64.3)15 weeks25--35Clinical and ultrasound improvement noted in 13 patients. In most patients, softening of sclerotic lesions was noted at the 15th treatment. Patients were followed up regularly for more than a year; there were two cases of recurrenceNoKerscher et al. \[[@CR54]\]Prospective uncontrolled study5Localized scleroderma3% ALA + PDT (10 J/cm^2^)Once or twice weeklyUnavailable3--6 months25--43A reduction of skin hardness and pruritus in lesions. In two patients, joint mobility was improved. One control plaque was untreated, and showed no signs of regressionNoKarrer et al. \[[@CR78]\]Retrospective study8Localized and systemic sclerodermaUVA115 J/cm^2^ 3 times a week. Then increased up to maximum dose of 30 J/cm^2^ for seven patients and 40 J/cm^2^ for three patientsRange 529--1029.4UnavailableRange 26--32Modified Rodnan skin score percentage improvement was 57%. One in remission for 12 months, four were in remission for 24 monthsOne patient on mycophenolate mofetil, one patient on pulsed cyclophosphamide, methotrexate, and ciclosporin. One patient on azathioprineRose et al. \[[@CR79]\]Retrospective study17Localized sclerodermaUVA15 times weekly750--14003--6 weeks19.3 ± 3.8Fourteen patients reported clinical improvementNoAndres et al. \[[@CR73]\]Retrospective study3Systemic sclerodermaUVA1Mean dose of 29.5 J/cm^2^Mean cumulative dose 1160 (range 660--1695)UnavailableMean 26Patients showed an improvement in the modified Rodnan scoring system. One patient had complete remissionUnknownPereira et al. \[[@CR80]\]Retrospective study18MorpheaUVA1Mean dose of 31 J/cm^2^Mean cumulative dose of 1662 (range 310--4270)UnavailableMean 3377.8% had marked improvement, 11.1% had moderate improvement, 5.6% had slight improvement, and 5.6% had no improvementUnknownPereira et al. \[[@CR80]\]Case series8Systemic sclerosisUVA130 J/cm^2^ 4 times a week for 8 weeks, then 3 times a week for 6 weeks150014 weeks50Modified Rodnan skin score improved after treatment. Seven patients experienced improvement in sclerosis in 6 months. Resulting in marked softening of skin and clinically significant improvement including finger mobilityUnknownVon Kobyletzki et al. \[[@CR81]\]Case series37MorpheaUVA1Treatments varied 2--5 times a week; 13 patients received 20 J/cm^2^ of UVA1. Eleven patients received 50--60 J/cm^2^ UVA1. Ten patients received medium-dose increased to high-dose 50--120 J/cm^2^. One patient received low-dose, followed by medium-dose UVA1 (60 treatments), and two patients received low-dose increased to high-dose UVA1 (mean 23.5 treatments, mean cumulative dose 2090 J/cm^2^)20 J/cm^2^ group mean 683.9, 50--60 J/cm^2^ group mean 1468.5, 50--120 J/cm^2^ group 2560Ranged20 J/cm^2^ group 11--78 (mean 35), 50--60 J/cm^2^ group 13--36 (mean 27.8), 50--120 J/cm^2^ group 9--41 (mean 20.7)26--100% improvement was found in 46.2% of patients treated with low-dose UVA1 phototherapy compared with 72.7% and 70% treated with medium and medium to high-dose UVA1, respectivelyUnknownTuchinda et al. \[[@CR85]\]Case series6Morphea/SS/CRESTUVA1UnavailableUnavailableUnavailable30--60Dermal thickness had decreased in five patientsNoOikarinen and Knuutinen \[[@CR82]\]Case series54SclerodermaUVA159.81 ± 27.40 J/cm^2^1203.15 ± 1133.95Unavailable21.10 ± 13.1Clinical improvement was noted by physician in 79.6% of patientsUnknownRombold et al. \[[@CR83]\]Case series8Localized sclerodermaUVA150 J/cm^2^ 5 times a week20008 weeks40The modified skin score improved in all patientsUnknownKreuter et al. \[[@CR84]\]Case series14Localized sclerodermaUVA120 J/cm^2^ 5 times a week8008 weeks40The modified skin score improved in all patientsUnknownKreuter et al. \[[@CR6]\]Case series12Systemic sclerosis/CRESTUVA1Treatments varied 2--5 times a weekUnavailableUnavailableUnavailable41.7% of patients experienced 51--100% improvementUnknownTuchinda et al. \[[@CR85]\]Case series2Localized sclerodermaPUVA0.2 J/cm^2^ up to a maximum dose of 20 J/cm^2^, 4 times a week over 5 weeks, then 2 times per week for an additional 5 weeksUnavailable10 weeks30Skin lesions cleared, ultrasound revealed normal ratio of treated skin thickness to uninvolved skinNoKerscher et al. \[[@CR42]\]Case series4Localized sclerodermaPUVAThe initial daily UVA doses were 1--1.5 J/cm^2^Range 242--405.512 weeks of PUVA daily, then maintenance PUVA treatment given twice or once per week for 3 months57--72The modified skin score improved after therapyAcitretinOzdemir et al. \[[@CR86]\]Case series13Localized morpheaPUVATwo patients treated with bath PUVA and all other patients with oral PUVA. Treatment was given twice weekly.Mean 135 (range 42--244)7--15 weeks14--30Mean reduction of 62.9% in modified Rodnan scoreFive patients had concurrent therapiesUsmani et al. \[[@CR30]\]Case series23Localized morpheaPUVAPatients were treated with a weekly regimen of bath immersion in 0.2 mg/l water solution of 8-methoxypsoralen, followed by irradiation with UVA 3 times a week with an initial UVA dose of 0.3 J/cm^2^, with subsequent increments of 0.3 J/cm^2^ added every 2--3 treatments up to a maximum dose of 10.0 J/cm^2^Mean 115UnavailableMean 71Eleven patients (39%) showed complete remission. Partial response in 14 patients (50%). In the complete remission group; no recurrence was observed in seven patients after a mean follow-up period of 7 months (range 1--18 months)NoPavlotsky et al. \[[@CR87]\]Case series4Linear and generalized morpheaPUVA oral3 times a week. UVA dose ranged from 42.5--94 J/cm^2^. After improvement (loss of induration), then maintenance treatment weekly and biweekly was givenUnavailableUnavailable44--88Number of treatments to show clearance ranged from 44--88. UVA dose to clear lesions ranged from 358--838.5 J/cm^2^NoMorison et al. \[[@CR88]\]Case series2En coup de sabrePUVA topicalInitial dose was 0.3 J/cm^2^. 3 times a week. And UVA dose was increased after 3 days with 0.2 J/cm^2^71Unavailable40Softening of lesions after 90 daysTopical calcipotriol twice a dayGambichler et al. \[[@CR100]\]Case series7Six with localized scleroderma, one with systemic sclerodermaPUVA topical4 times a week. Highest UVA dose per treatment mean was 3.5 J/cm^2^Mean 53.5UnavailableMean 25 (range 14--39)Marked improvement in softening of sclerotic plaques in all patientsUnknownPasic et al. \[[@CR89]\]Case series10SclerodermaWater-filtered infrared A plus visible light treatmentTotal irradiance was 180--200 mW/cm^2^. Treatment was done 2--5 times a week.UnavailableUnavailable16--48Seven patients reported improvement, follow-up was 1--7.5 years after treatmentUnknownVon Felbert et al. \[[@CR90]\]Case report16/FNodular morpheaPUVA topicalUnavailable2.32UnavailableUnavailableSlight improvement of regression of nodules. The patient was lost to follow-upPenicillin G for 10 daysKauer et al. \[[@CR91]\]Case report12/FLocalized sclerodermaPUVA topical0.2--4.0 J/cm^2^ to total dose of 62.8 J/cm^2^. Initiated for 10 days, then subsequently once a week for 4 monthsUnavailable4 monthsUnavailableRodnan score + range of motion of affected joint improvementOral prednisoloneUchiyama et al. \[[@CR92]\]Case report43/FSystemic sclerosisPUVA topicalUVA dose started at 0.6 J/cm^2^ then gradually increased to 2.4 J/cm^2^. Treatments were given once a week167.3Unavailable107Significant softening of the affected areas, and normalization of skin temperatureNoMorita et al. \[[@CR93]\]Case report58/MSystemic sclerosisPUVA topical0.10 J/cm^2^ 3 times a week, increasing to a maximum single dose of 8 J/cm^2^272.329 weeksUnavailableDecreased necrosis in fingers, reduced symptoms of swelling, erosions, crusting, and induration in fingers. Follow-up at 5 months showed slight swelling of both hands without new fingertip lesionsSildenafil 150 mg dailyMohanna et al. \[[@CR94]\]Case report65/FGeneralized morpheaPUVA0.4 J/cm^2^ 3 times a weekUnavailable8 weeks24Hand closure and skin sclerosis index. Score went from three to one. Disease free after 2-year follow-up with weekly maintenance therapyNoKanekura et al. \[[@CR95]\]Case report61/MProgressive systemic sclerosisPUVA0.25 J/cm^2^ 4 times a week. Total dose of 5 J/cm^2^.Unavailable5 weeks20Hand closure and skin sclerosis index improved from 4 to 1NoKanekura et al. \[[@CR95]\]Case report42/MProgressive systemic sclerosisPUVAPUVA 0.4 J/cm^2^ 6 times a week. Total dose of 7.2 J/cm^2^.Unavailable3 weeks18Hand closure and skin sclerosis index improved from 3 to 0NoKanekura et al. \[[@CR95]\]Case report32/FProgressive systemic sclerosisPUVAPUVA 0.25 J/cm^2^ twice a week. Total dose of 3.5 J/cm^2^.Unavailable7 weeks14Skin sclerosis index improved from 3 to 1NoKanekura et al. \[[@CR95]\]Case report80/MLocalized sclerodermaPUVAInitial 3 times weekly UVA dose of 4 J/cm^2^, which was gradually increased, weekly, to a maximal single dose of 18 J/cm^2^Unavailable11 months127After 9 months, the skin plaques were softening. Treatment was then continued twice every week for another 2 months. After 127 treatments, there was clearance of the lesion. Clinical stability remained after 8 monthsNoGarcia-Bustinduy et al. \[[@CR96]\]Case report7/FPansclerotic morpheaPUVA0.6 mg/kg for 4 times a week. Dose started at 0.5 J/cm^2^ and was gradually increased to 2.0 J/cm^2^ over 2 monthsUnavailable10 weeksUnavailableAfter 10 weeks her condition worsened with spread of disease, ulceration and contraction deformitiesPenicillamine 20 mg/kg/dayTodd et al. \[[@CR97]\]Case report56/FSystemic sclerosisPUVA3 times a week. Then once a week for maintenance therapy once improvement seen48319 monthsUnavailable100% improvement (patient self-evaluation)NoBaum et al. \[[@CR98]\]Case report66/MSystemic sclerosisPUVA3 times a week then once a week for maintenance therapy once improvement seen201.5 monthsUnavailable\>70% response rate (patient self-evaluation)NoBaum et al. \[[@CR98]\]Case report27/MGeneralized morpheaPUVA3 times a week, then once a week for maintenance therapy once improvement seen28810 monthsUnavailable\>70% response rate (patient self-evaluation)NoBaum et al. \[[@CR98]\]Case report40/MDiffuse morpheaPUVATwice weekly at 5 J/session11523 monthsN/AIncreased mobility, reduced progression of plaques and sclerosisCyclosporine for 2 years. Then transitioned to mycophenolate mofetil for 1 year and phototherapy discontinuedRose and Goodfield  \[[@CR99]\]Case report64/FDisseminated sclerodermaPUVAInitial dose of 0.76 J/cm^2^, maximum tolerated dose 10 J/cm^2^. The first 28 treatments were conducted 4 times a week. Then twice a week during the following ten treatmentsUnavailableUnavailableUnavailableThe skin sclerosis index was a four before therapy, and a one or two after therapy. Improvement was also noted from infrared thermography before and after treatment. No recurrence approximately 2 years laterNoAragane et al. \[[@CR101]\]Case report27/FLocalized sclerodermaPUVA0.4 J/cm^2^ up to a total dose of 5 J/cm^2^UnavailableUnavailableUnavailableClinical improvement observed with reduced hardness. No recurrence after 20-month follow-upNoYamaguchi et al. \[[@CR102]\]Case report12/MPansclerotic morpheaPUVAUnavailableUnavailableUnavailableUnavailableImprovement in skin and ulceration that lasted 1.5 yearsUnknownWollina et al. \[[@CR103]\]Case report40/FPost-radiation morpheaPUVATwice weekly for 22 treatments (107.8 J/cm^2^). Patient subsequently had 47 treatments of UVA1. This was started at medium dose (35 treatments at 50 J/cm^2^) and progressed to high dose (12 treatments at 80 J/cm^2^2633.6Unavailable69Patient reported better improvement with high-dose UVA1 then medium-dose UVA1NoLim et al. \[[@CR104]\]Case report8/FPansclerotic morpheaPUVAUVA dose 0.5 J/cm^2^, which was gradually increased to 1.8 J/cm^2^ during the next 2 months using four irradiations weekly. She was maintained on two treatments per week for 6 monthsUnavailableUnavailable68Softening of skin was observed within 1st month. Improved healing of ulcers and joint mobility. No evidence of relapse after a 14 month follow-upNoScharffetter-Kochanek et al. \[[@CR105]\]Case report72/FTraumatic sclerodermaUVA170 J/cm^2^ 5 times a week14004 weeksUnavailableDurometer scores improved significantly during first 3 weeks and borderline significantly the last week. Remission after \>31 monthsNoKroft et al. \[[@CR44]\]Case report8/FPansclerotic morpheaUVA15 J/cm^2^ 3 times a week. Then the doses were increased gradually to a maximum of 20 J/cm^2^480UnavailableUnavailableImprovement was seen at 10--12 sessions. Softening of sclerotic lesions. Hypopigmented areas began to have pigmentationNoYildirim et al. \[[@CR106]\]Case report45/FSystemic sclerosisUVA150 J/cm^2^ 2--3 times a week2222Unavailable40Microstomia had improved; all of her sclerotic lesions were softer. She could articulate words normally and had reduced furrowing around the mouthUnknownTewari et al. \[[@CR107]\]Case report19/FSclerodermaUVA120 J/cm^2^ 5 times a weekUnavailableUnavailableUnavailableSoftening of fibrotic skin, improved mobility of jointsMethylprednisolone, methotrexate, pentoxiflyin, asprin, and piascledineForsea, et al. \[[@CR108]\]Case report71/MPansclerotic morpheaUVA130 J/cm^2^ 3 times a week135015 weeks45Softening, increased elasticityNoHerzinger et al. \[[@CR109]\]Case report16/MPansclerotic morpheaUVA120 J/cm^2^ 4 times a week6408 weeks32Within 3 weeks there was softening of the skin on the trunk and head. There was an increase in joint mobility. Therapeutic effects lasted for 6 monthsNoGruss et al. \[[@CR110]\]Case report42/FProgressive systemic sclerosisUVA20 J/cm^2^ 3 times a weekUnavailableUnavailableUnavailableSoftening of facial sclerosis softening and decreased pruritus at 3 week. At 2 months, lesions on her abdomen and upper legs softenedUnknownSteger and Matthews \[[@CR111]\]Case report11/MLocalized sclerodermaUVA20 J/cm^2^ 4 times a week for 6 weeks, then once weekly for 6 weeksUnavailable12 weeksUnavailableLesion cleared with softening, tanning, and thinning of the skin. At 3-month follow-up the lesion is still in remissionNoSteger and Matthews \[[@CR111]\]Case report32/FEn coup de sabreNarrowband UVB3 times a weekUnavailable24 weeksN/APrevented progression of disease. Patient remained stable for a year off of UVB, but then disease recurred and had to resume UVB and oral colchicineNoBrownell et al. \[[@CR112]\]Case report22/FSecondary cicatricial alopecia/sclerodermaNon-ablative fractional laserFluence of 6--8 mJ and a density of 300 spots/cm^2^/pass. For ablative fractional laser, a fluence of 30--50 mJ was delivered to the affected area 150 spots/cm^2^UnavailableNon-ablative/ablative laser with a 4 week interval between treatments15Eight treatments before clinical improvement observed. 26--50% clinical improvement assessmentTopical calcipotriol cream 0.005%Cho et al. \[[@CR113]\]Case report34/MSecondary cicatricial alopecia/sclerodermaNon-ablative fractional laserFluence of 6--8 mJ and a density of 300 spots/cm^2^/pass. For ablative fractional laser, a fluence of 30--50 mJ was delivered to the affected area 150 spots/cm^2^UnavailableNon-ablative/ablative laser with a 4 week interval between treatments20Five treatments before clinical improvement observed. 26--50% clinical improvementTopical calcipotriol cream 0.005%Cho et al  \[[@CR113]\]Case report41/FMorphea585-nm long pulsed (1.5 ms) dye laserFour treatments, 2 weeks between treatments. 5 J/cm^2^ fluenceUnavailable8 weeks4Softening of the plaque noted after each treatment. 6 months after 1st treatment, there was clinical stabilityNoEisen and Alster \[[@CR114]\]*ALA* aminolevulinic acid, *F* female, *M* male, *PDT* photodynamic therapy, *PUVA* psoralen and ultraviolet, *UVA* ultraviolet A, *UVA1* ultraviolet A1, *UVB* ultraviolet B^a^Total number, if case report age/gender

Skin darkness or darkening likely has no effect on UVA1's efficacy. Forty-seven patients with morphea and 35 with SSc treated with UVA1 phototherapy were analyzed to see whether Fitzpatrick skin type makes an impact on the outcome, with the result being that medium- to high-dose UVA1 had similar efficacy in skin types I--V \[[@CR48]\]. There was also no correlation noted for Fitzpatrick skin type and cumulative dose or clinical improvement.

The current evidence suggests that UVA1 effects are dose-related. In an observational report for patients with SSc who completed at least ten treatments, 20% of those treated with low-dose (20--40 J/cm^2^) UVA1 (*n* = 5), 83.3% of those treated with medium-dose (\>40--80 J/cm^2^) UVA1 (*n* = 6), and 100% of those treated with high-dose (\>80--120 J/cm^2^) UVA1 (*n* = 5) reported improvement \[[@CR49]\]. A 14-patient study showed a 70-J/cm^2^ dose was more effective in treating localized scleroderma lesions than a 20 J/cm^2^ dose \[[@CR45]\]. In six patients with localized scleroderma treated two to three times a week, three patients experienced complete remission \[[@CR50]\]. Two of the three received high-dose 100 J UVA1 therapy, of which one of them received 67 treatments and relapsed after 6 months, compared to one patient which received low-dose UVA1 twice weekly for 6 weeks for a total of 39 irradiations and did not relapse after 84-month follow up \[[@CR50]\]. A broadband UVA trial examined 63 patients with morphea and 15 patients treated with UVA1 5, 10, or 20 J/cm^2^ with cumulative doses of 100, 200, and 400 J/cm^2^, respectively \[[@CR51]\]. Clinical improvement was observed in all patients, but there was no comparable difference between the UVA doses.

Long-term outcome of UVA1 therapy is unclear. In a cohort study of 37 patients with morphea with positive clinical benefits from UVA1 treatment 44.5% recurred at 2 years, and 48.4% recurred at 3 years \[[@CR52]\]. There was no difference between medium- (60--90 J/cm^2^) and high-dose (\>90 J/cm^2^) UVA1 phototherapy with respect to recurrence. There was a 1.15-times higher chance of disease recurrence for an increment of 1 year in duration of morphea prior to UVA1 treatment \[[@CR52]\].

Broadband UVA {#Sec7}
-------------

Twelve patients with morphea were treated with low-dose (20 J/cm^2^) broadband UVA 3 times a week for a total of 20 sessions \[[@CR12]\]. Improved softness of skin lesions assessed by palpation was reported as early as three treatments and as late as ten treatments. Longer standing lesions did not respond as well as therapy. As a control, some lesions in the same patients were covered to prevent UVA1 exposure during treatment, and less softening was reported in these covered lesions. After a 1-year follow-up, only two patients reported a reappearance of lesions. Lesions on skin creases or over joints did not respond as well to therapy \[[@CR12]\].

PUVA {#Sec9}
----

A 15-year-old male with scleroderma with indurated patches on the trunk and joint restrictions was recalcitrant to hydroxychloroquine, prednisolone, and methotrexate \[[@CR53]\]. PUVA at a dose of 0.6 mg/kg twice weekly was subsequently added for 20 sessions over 10 weeks at a cumulative dose of 25.4 J/cm^2^. Methotrexate was subsequently administered for 7 months. After this period, he was able to make a full fist and increase to a normal range of motion in the ankles; his skin was less indurated and has maintained clinical stability for 2 years \[[@CR53]\]. Table [1](#Tab1){ref-type="table"} lists additional PUVA treatment studies in scleroderma/morphea. PUVA's effects may be due to local effects rather than systemic effects, as Kerscher et al. \[[@CR54]\] noted that residual sclerotic lesions remained in patients in areas hidden from UVA exposure such as parts of the elbow in patients undergoing PUVA.

UVB {#Sec10}
---

A 43-year-old female with radiation-induced morphea was given acitretin daily and UVB three times a week \[[@CR55]\]. Two months afterwards there was less induration of her plaque, decreased tenderness, and improved range of motion of the left arm \[[@CR55]\]. Eleven patients that underwent phototherapy treatment (seven treated with PUVA and four treated with narrowband UVB) for an average of ten sessions experienced a 48% improvement of their localized scleroderma as indicated by a clinical pinching test \[[@CR56]\]. Additionally, the ultrasound examination showed a dermal thickness reduction ranging from 20% to 100% \[[@CR56]\]. There was no correlation between the type of phototherapy and clinical response rate \[[@CR56]\]. Additional studies on UVB therapies are included in Table [1](#Tab1){ref-type="table"}.

Targeted Phototherapy {#Sec11}
---------------------

Targeted phototherapy is a modality that spares non-lesional skin and is able to deliver a higher fluence. A patient with limited scleroderma and elbow mobility restrictions was treated 2--3 times a week for 13 weeks with 940-nm low-level light therapy with millisecond pulsing and continuous wave modes. Using a sequential pulsing dose on one elbow and continuous wave mode on the other, better results were seen with the pulsing mode showing improvement in skin thickness \[[@CR57]\].

Five patients with a total of 11 plaques were treated with a 308-nm monochromatic excimer laser for 4 weeks at a power density of 48 mW/cm^2^ with a maximum irradiation area of 512 cm^2^ \[[@CR58]\]. The mean number of treatments was seven, and the dose per session was 1.5 J/cm^2^. The mean total dose was 10 J/cm^2^. After 4 weeks, 3 out of 5 patients experienced marked improvement with residual hyperpigmentation \[[@CR58]\].

A 27-year-old Hispanic female had a contracture of her knee with sclerotic bands on her left lower leg, ankle, and foot that were recalcitrant to methotrexate, UVA1, topical calcipotriene, intralesional triamcinolone acetonide, and physical therapy \[[@CR59]\]. The patient was treated with a single treatment of 10.6 µm carbon dioxide laser with a 50 J/cm^2^ pulse energy, while remaining on methotrexate and topical agents \[[@CR59]\]. After 1 week, she experienced an increase in range of motion. After 4 months of follow-up, there was softening of her contracture, and she regained full plantar flexion of her left foot. After a 1-year follow-up, she maintained a full range of motion \[[@CR59]\].

Four patients with microstomia and SSc were treated with intense pulsed light. 530--570 mm, 11--14 J/cm^2^; 10--14 pulse durations was used for the patients every 4 weeks \[[@CR60]\]. Patients were followed for 4 months. Three patients experienced an increased interincisal distance of \~1 mm per treatment \[[@CR60]\]. One patient did not have improved interincisal distance, but did note activities of daily living became easier. One patient did report recurrence of the stiffness after 3 weeks \[[@CR60]\]. Table [1](#Tab1){ref-type="table"} lists additional reports of targeted phototherapy.

Photodynamic Therapy {#Sec12}
--------------------

In six patients, 20% 5-ALA was applied under occlusion to areas of morphea for 5 h. A band width of 570--670 nm, peak 635-nm light was given. A dose of 25 J/cm^2^ was given for a total of six weekly treatments. In four of the patients there was clinical improvement as determined by skin scoring, although only one of these patients showed histologic evidence of improvement. The side effects patients reported included burning sensation, dryness, erythema, pigmentation, and pruritus \[[@CR61]\]. Table [1](#Tab1){ref-type="table"} lists an additional study.

Discussion {#Sec13}
==========

There are mostly care reports of UVA1, UVB, PUVA (bath and topical), and targeted phototherapies in cases of scleroderma. UVA1 appears to be the most efficacious, but it is also the most studied. There are not many studies on high-dose UVA1, and this needs to be investigated further to assess the optimal dose of UVA to use in scleroderma. Additionally, longer term studies are needed to study the long-term outcome and safety of these treatments. A similar literature review study delineated UVA and PUVA's efficacy and safety in the context of SSc, localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermoid graft-versus-host disease, lupus erythematosus, and other rare sclerotic diseases \[[@CR62]\]. This review also asserts that there need to be more rigorous studies to help establish a guide for UVA's indications as well as its efficacy compared to other conventional medical therapies \[[@CR62]\].

Based on the studies available, a reasonable regimen is UVA1 therapy 20--50 J/cm^2^ 3--4 times a week for a total of 30 treatments. There were no double-blind, placebo-controlled trials available, and only three controlled trials. Adverse effects thus far do not correlate with the intensity of therapy. The side effects noted in scleroderma phototherapy include fatigue, a burning sensation, hyperpigmentation, pruritus, erythema, edema, headaches, gastrointestinal upset, and joint and muscle pain. Additionally, one patient undergoing UVA1 phototherapy for disseminated morphea developed bullous pemphigoid after 29 treatments \[[@CR63]\]. The long-term effects of UVA1 on patients have not reported skin cancer \[[@CR64]\]. Phototherapy should be safe in pregnancy \[[@CR65]\] although folate may need to be supplemented as reports show that UVB and solar UV radiation may cause photodegradation \[[@CR66], [@CR67]\]. Multiple treatments, as well as limited availability of in-office phototherapy, are barriers to treatment. In a review by Bielsa Marsol \[[@CR68]\], it was pointed out that most of the studies for UVA1 therapy were performed in countries where patients are predominantly Fitzpatrick types I--III, although, as noted earlier, the Fitzpatrick skin type thus far has not been shown to have an impact on therapy. Phototherapy may not be as useful for sclerotic diseases that affect structures deeper than the dermis.
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